Immunology Faculty Member - Joseph Sodroski, MD

Joseph Sodroski, MD

Dana Farber Cancer Institute
450 Brookline Avenue
CLS Building, Room 1010
Boston, MA 02115
Tel: 617-632-3371
Fax: 617-632-4338

The major interests of the laboratory are the early events in human immunodeficiency virus (HIV-1) infection. Understanding and blocking these early events are critical to interrupting HIV-1 transmission and changing the course of the global AIDS pandemic. The laboratory studies HIV-1 entry into cells, a process that is mediated by the viral envelope glycoproteins. These glycoproteins bind receptors on the target cell and fuse viral and cell membranes. The conformational transitions of the HIV-1 envelope glycoproteins that contribute to virus entry are being characterized. The laboratory is devoted to understanding HIV-1 entry at the molecular level, and identifying and characterizing inhibitors. The interaction of small-molecule entry inhibitors and neutralizing antibodies with the HIV-1 envelope glycoproteins is being studied.

In virus-producing cells, expression of the HIV-1 envelope glycoproteins results in cytopathic effects. These toxic effects result from the membrane-fusing activity of the HIV-1 envelope glycoproteins, which results in damage to the host cell membranes. The contribution of these processes to the depletion of CD4-positive T lymphocytes in vivo is being studied.

Last Update: 7/12/2018


Madani N, Princiotto AM, Easterhoff D, Bradley T, Luo K, Williams WB, Liao H-X, Moody MA, Phad GE, Vasquez Bernat N, Melillo B, Santra S, Smith AB III, Karlsson Hedestam GB, Haynes B and Sodroski J. Antibodies elicited by multiple envelope glycoprotein immunogens in primates neutralize primary human immunodeficiency viruses (HIV-1) sensitized by CD4-mimetic compounds. J Virol 2016; 90:5031-5046.

Herschhorn A, Ma X, Gu C, Ventura JD, Castillo-Menendez L, Melillo B, Terry DS, Smith AB III, Blanchard SC, Munro JB, Mothes W, Finzi A and Sodroski J. Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins. MBio 2016; 7:e01598-16.

Madani N, Princiotto AM, Zhao C, Jahanbakhshsefidi F, Mertens M, Herschhorn A, Melillo B, Smith AB III and Sodroski J. Activation and inactivation of primary human immunodeficiency virus envelope glycoprotein trimers by CD4-mimetic compounds. J Virol 2017; 91:e01880-16.

Herschhorn A, Gu C, Moraca F, Ma X, Farrell M, Smith AB III, Pancera M, Kwong PD, Schön A, Freire E, Abrams C, Blanchard SC, Mothes W and Sodroski JG. The β20-β21 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. Nat Commun 2017; 8:1049.
Madani N, Princiotto AM, Mach L, Ding S, Prevost J, Richard J, Hora B, Sutherland L, Zhao CA, Conn BP, Bradley T, Moody MA, Melillo B, Finzi A, Haynes BF, Smith AB III, Santra S, Sodroski J. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nat Commun 2018; 9:2363.
Castillo-Menendez LR, Witt K, Espy N, Princiotto A, Madani N, Pacheco B, Finzi A, Sodroski J. Comparison of uncleaved and mature human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimers. J Virol 2018; 92:e00277-18.
Complete List of Published Work in MyBibliography:

© 2016 President and Fellows
of Harvard College